Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

GlaxoSmithKline UK
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 10/12/2007
SPC Dermovate Scalp Application

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 10/12/2007 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
Date of revision of text on the SPC:   11/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

update section 4.8 of the SPC to reflect the MedDRA SOC format and frequencies assigned according to CIOMS, as per current guidance
Updated on 18/04/2007 and displayed until 10/12/2007
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   02/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 7 - update trading style
Updated on 18/04/2007 and displayed until 18/04/2007
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   02/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7 has been updated with trading style

Updated on 03/04/2007 and displayed until 18/04/2007
Reasons for adding or updating:
  • Change of Marketing Authorisation Holder
Date of revision of text on the SPC:   02/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
 
7.         Marketing Authorisation Holder
             Glaxo Wellcome UK Ltd
             trading as
            Glaxo Laboratories and/or GlaxoSmithKline UK
Updated on 14/02/2007 and displayed until 03/04/2007
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   02/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

For further information, please contact GlaxoSmithKline on +44 (0)800 221 441
Updated on 04/04/2006 and displayed until 14/02/2007
Reasons for adding or updating:
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 10 (date of (partial) revision of the text
Updated on 10/03/2003 and displayed until 04/04/2006
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Updated on 11/08/2001 and displayed until 10/03/2003
Reasons for adding or updating:
  • No reasons supplied
Updated on 12/07/2000 and displayed until 11/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 27/01/2000 and displayed until 12/07/2000
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 27/01/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  clobetasol propionate